Overview

Universal Chimeric Antigen Receptor T-Cell UCAR T-cell Therapy Targeting CD19/B Cell Maturation Antigen CD19/BCMA in Patients With r/r Neurological Autoimmune Diseases

Status:
NOT_YET_RECRUITING

Trial end date:
2027-10-01

Target enrollment:

Participant gender:

Summary

This is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells.

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

Tianjin Huanhu Hospital

Collaborator:

Shanghai Xiniao Biotech Co., Ltd.